Acute Kidney InjuryNCT06722924
Definition of Acute Kidney Injury by Urine Output in Critically Ill Patients
An observational study of Acute Kidney Injury and Critical Illness, run by Uppsala University.
Trial summary
The goal of this observational study is to explore the association between urine output and acute kidney injury in severely ill patients admitted to intensive care units. The main research questions are: What is the optimal threshold for defining reduced urine output in critically ill patients in intensive care? Is… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Kidney Injury, Critical Illness, Critical Care, Intensive Care
- How many people
- 15,000 participants
- Where
- No sites listed yet
- Study dates
- Dec 2024to Mar 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population will be adult patients (>17 years of age) who have received care in the intensive care unit at Akademiska Sjukhuset since the implementation of the Metavision (an electronic medical record system used in anesthesia and intensive care (Patient Data Management System, PDMS)) from 2016-2017 (depending on the unit) up until the study start in 2024. To enable subgroup analyses and improve the reliability of estimates, the largest possible cohort is desired. Children will not be included in the study, as their urine production and normal reference values for blood markers of kidney function vary with age and differ from those of adults.
Who may be able to join
- Admittance to intensive care units at Uppsala University Hospital between 2016-2024
Who cannot join
- Minimum age 18 years
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Definition of Acute Kidney Injury Based on Urine Output
The goal of this observational study is to explore the association between urine output and acute kidney injury in severely ill patients admitted to intensive care units. The main research questions are:
What is the optimal threshold for defining reduced urine output in critically ill patients in intensive care? Is this threshold the same for different outcomes such as acute kidney injury, chronic kidney dysfunction, or mortality? Does this threshold change with treatment involving diuretics or dialysis? Does the patient's fluid balance or the amount of administered fluid affect the association between reduced urine output and the outcomes mentioned above? Is the optimal threshold for defining reduced urine output different for various patient categories and diagnoses, such as sepsis, burn injuries, or ARDS? Are there differences between surgical and non-surgical patients regarding the optimal threshold for defining reduced urine output in intensive care? Does the patient's comorbidity influence the level of reduced urine output that should be considered pathological?
Read the detailed description
Acute Kidney Injury (AKI) is a common occurrence in critically ill patients in intensive care units and is strongly associated with an increased risk of complications, longer hospital stay and mortality. Research in this area was long hampered by the lack of a unified definition, but since 2012, there has been a widely accepted consensus definition for AKI: the KDIGO Clinical Practice Guideline for Acute Kidney Injury. This has facilitated comparisons of different studies and interventions.
According to this definition, AKI is based on either a) an acute elevation in blood creatinine levels (a breakdown product normally excreted in the urine) and/or b) reduced urine output. Kidney injury is further graded into three stages (1-3) based on increasing creatinine levels or decreasing urine output, where higher stages indicate worse kidney function and an increased risk of mortality.
However, the current definition of AKI also has weaknesses and limitations. Creatinine, a breakdown product primarily produced in the muscles, increases in the blood with kidney injury but reflects not the injury itself, but rather the impaired kidney function resulting from the injury. Thus, creatinine serves as a marker of kidney function rather than kidney injury, with elevated levels often appearing one or more days after the injury occurs. Additionally, creatinine levels are influenced by other factors unrelated to kidney function, such as an individual's muscle mass.
Urine output changes earlier than creatinine levels in cases of kidney injury and is easy to measure in intensive care patients, most of whom have urinary catheters. Reduced urine output is associated with an increased risk of mortality in intensive care patients, even when creatinine levels are normal. KDIGO defines reduced urine output as less than 0.5 milliliters of urine per kilogram of body weight per hour. However, this definition, which is essentially based on older studies of normal physiology, has been questioned in recent years. Reduced urine output is a normal physiological response to stress, such as surgery, making it challenging to distinguish physiological reductions in urine output from AKI. Several modern studies in surgical and intensive care contexts suggest that urine output lower than 0.5 ml/kg/h does not increase the risk of AKI or mortality. Based on these findings, lower thresholds have been proposed as a definition of AKI. More knowledge and studies that consider factors beyond urine output are needed to validate these findings. For instance, we lack knowledge about whether the relationship between urine output and patient outcomes is influenced by diuretic therapy, the amount of fluid administered, or fluid balance.
This research project aims to identify a possible threshold for urine output that reliably indicates AKI. The goal is also to examine the relationship between urine output and the severity of AKI, the need for renal replacement therapy (dialysis), long-term effects on kidney function, and mortality risk.
All adult patients treated in the intensive care unit at Uppsala University Hospital between 2016 and 2024 (up to the start of the study) will be included. Patients are identified through the Patient Administrative System for Intensive Care Units (PasIva). PasIva is an administrative support system used to report data to the Swedish Intensive Care Registry (SIR). Local data may need to be supplemented with information from SIR if necessary. The system provides data on reasons for ICU admission, severity of illness upon admission, interventions during intensive care, and 30- and 90-day mortality. Data in PasIva cannot be uploaded unless it is registered and formatted according to SIR's templates, ensuring validity.
From the local system Metavision, an electronic medical record system used in anesthesia and intensive care (Patient Data Management System, PDMS), data is retrieved on physiological variables such as urine output, fluid balance, body weight, medication, and organ-supportive treatments like renal replacement therapy (dialysis). Data is entered into Metavision hourly by ICU staff, ensuring high-resolution records. All medications administered in the relevant units are prescribed in Metavision.
From the medical record system COSMIC and databases managed by the Academic Laboratory at Uppsala University Hospital, data is collected on previous medical conditions, blood test results such as creatinine, and findings from diagnostic examinations. The Academic Laboratory is quality assured and accredited by SWEDAC according to SS-EN ISO 15189.
Patient data from the above sources will be merged to enable analysis. Data will be reviewed using standard procedures (e.g., measures of dispersion, plots) to detect anomalies indicative of errors in registration. We plan to divide the cohort into a subset for analysis and another for validation of the results. Multivariable statistical models will be applied to address the scientific questions described above.
- Conditions
- Acute Kidney Injury, Critical Illness, Critical Care, Intensive Care, Critical Care, Fluid Resuscitation
- Keywords
- observational study
- Medical subject headings
- Acute Kidney Injury, Critical Illness
What is being measured
The primary outcome is the main question the study is designed to answer.
Acute Kidney Injury according to KDIGO creatinine criteria.
AKI by creatinine criteria is defined as any of the following: 1) Increase in SCr by ≥26.5 umol/l within 48 hours; or 2) Increase in SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days.
Further, the severity of AKI is staged in 3 levels: 1) SCr 1.5-1.9 times baseline OR ≥26.5 umol/l increase; 2) SCr 2.0-2.9 times baseline; 3) SCr 3.0 times baseline OR increase in serum creatinine to ≥353.6 umol/l OR initiation of renal replacement therapy
Measured: Seven days rolling window.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Dec 2024
- Study startDec 2024 (estimated)
- Primary completionJan 2025 (estimated)
- Study completionMar 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Kidney InjuryStudies of the same condition, open and under way.
- More trials run by Uppsala UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 15,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Uppsala University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06722924
- Sponsor's protocol ID
- AKI-UO
- Status last verified
- Dec 2024
- First submitted
- 3 Dec 2024
- Last updated
- 9 Dec 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: We are not allowed to share individual patient data according to decision in Swedish Ethical Review Authority. If a third party upon reasonable request present a valid authorization from the responsible government agency we might be allowed to share the data if we submit an amendment to the Swedish Ethical Review Authority.
Study at a glance
From the registry record, last updated by the sponsor on 9 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Definition of Acute Kidney Injury Based on Urine Output
- ClinicalTrials.gov ID
- NCT06722924
- Acronym / sponsor ID
- AKI-UO
- Conditions
- Acute Kidney Injury, Critical Illness, Critical Care, Intensive Care, Critical Care, Fluid Resuscitation
- Keywords
- observational study
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 15,000 participants (estimated)
- Lead sponsor
- Uppsala UniversityUniversity, hospital or other
- Study start
- Dec 2024 (estimated)
- Primary completion
- Jan 2025 (estimated)
- Study completion
- Mar 2025 (estimated)
- First posted
- 9 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to explore the association between urine output and acute kidney injury in severely ill patients admitted to intensive care units. The main research questions are:
What is the optimal threshold for defining reduced urine output in critically ill patients in intensive care? Is this threshold the same for different outcomes such as acute kidney injury, chronic kidney dysfunction, or mortality? Does this threshold change with treatment involving diuretics or dialysis? Does the patient's fluid balance or the amount of administered fluid affect the association between reduced urine output and the outcomes mentioned above? Is the optimal threshold for defining reduced urine output different for various patient categories and diagnoses, such as sepsis, burn injuries, or ARDS? Are there differences between surgical and non-surgical patients regarding the optimal threshold for defining reduced urine output in intensive care? Does the patient's comorbidity influence the level of reduced urine output that should be considered pathological?
Detailed description
Acute Kidney Injury (AKI) is a common occurrence in critically ill patients in intensive care units and is strongly associated with an increased risk of complications, longer hospital stay and mortality. Research in this area was long hampered by the lack of a unified definition, but since 2012, there has been a widely accepted consensus definition for AKI: the KDIGO Clinical Practice Guideline for Acute Kidney Injury. This has facilitated comparisons of different studies and interventions.
According to this definition, AKI is based on either a) an acute elevation in blood creatinine levels (a breakdown product normally excreted in the urine) and/or b) reduced urine output. Kidney injury is further graded into three stages (1-3) based on increasing creatinine levels or decreasing urine output, where higher stages indicate worse kidney function and an increased risk of mortality.
However, the current definition of AKI also has weaknesses and limitations. Creatinine, a breakdown product primarily produced in the muscles, increases in the blood with kidney injury but reflects not the injury itself, but rather the impaired kidney function resulting from the injury. Thus, creatinine serves as a marker of kidney function rather than kidney injury, with elevated levels often appearing one or more days after the injury occurs. Additionally, creatinine levels are influenced by other factors unrelated to kidney function, such as an individual's muscle mass.
Urine output changes earlier than creatinine levels in cases of kidney injury and is easy to measure in intensive care patients, most of whom have urinary catheters. Reduced urine output is associated with an increased risk of mortality in intensive care patients, even when creatinine levels are normal. KDIGO defines reduced urine output as less than 0.5 milliliters of urine per kilogram of body weight per hour. However, this definition, which is essentially based on older studies of normal physiology, has been questioned in recent years. Reduced urine output is a normal physiological response to stress, such as surgery, making it challenging to distinguish physiological reductions in urine output from AKI. Several modern studies in surgical and intensive care contexts suggest that urine output lower than 0.5 ml/kg/h does not increase the risk of AKI or mortality. Based on these findings, lower thresholds have been proposed as a definition of AKI. More knowledge and studies that consider factors beyond urine output are needed to validate these findings. For instance, we lack knowledge about whether the relationship between urine output and patient outcomes is influenced by diuretic therapy, the amount of fluid administered, or fluid balance.
This research project aims to identify a possible threshold for urine output that reliably indicates AKI. The goal is also to examine the relationship between urine output and the severity of AKI, the need for renal replacement therapy (dialysis), long-term effects on kidney function, and mortality risk.
All adult patients treated in the intensive care unit at Uppsala University Hospital between 2016 and 2024 (up to the start of the study) will be included. Patients are identified through the Patient Administrative System for Intensive Care Units (PasIva). PasIva is an administrative support system used to report data to the Swedish Intensive Care Registry (SIR). Local data may need to be supplemented with information from SIR if necessary. The system provides data on reasons for ICU admission, severity of illness upon admission, interventions during intensive care, and 30- and 90-day mortality. Data in PasIva cannot be uploaded unless it is registered and formatted according to SIR's templates, ensuring validity.
From the local system Metavision, an electronic medical record system used in anesthesia and intensive care (Patient Data Management System, PDMS), data is retrieved on physiological variables such as urine output, fluid balance, body weight, medication, and organ-supportive treatments like renal replacement therapy (dialysis). Data is entered into Metavision hourly by ICU staff, ensuring high-resolution records. All medications administered in the relevant units are prescribed in Metavision.
From the medical record system COSMIC and databases managed by the Academic Laboratory at Uppsala University Hospital, data is collected on previous medical conditions, blood test results such as creatinine, and findings from diagnostic examinations. The Academic Laboratory is quality assured and accredited by SWEDAC according to SS-EN ISO 15189.
Patient data from the above sources will be merged to enable analysis. Data will be reviewed using standard procedures (e.g., measures of dispersion, plots) to detect anomalies indicative of errors in registration. We plan to divide the cohort into a subset for analysis and another for validation of the results. Multivariable statistical models will be applied to address the scientific questions described above.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will be adult patients (>17 years of age) who have received care in the intensive care unit at Akademiska Sjukhuset since the implementation of the Metavision (an electronic medical record system used in anesthesia and intensive care (Patient Data Management System, PDMS)) from 2016-2017 (depending on the unit) up until the study start in 2024. To enable subgroup analyses and improve the reliability of estimates, the largest possible cohort is desired. Children will not be included in the study, as their urine production and normal reference values for blood markers of kidney function vary with age and differ from those of adults.
Key inclusion criteria (1 listed)
- Admittance to intensive care units at Uppsala University Hospital between 2016-2024
Key exclusion criteria (1 listed)
- Minimum age 18 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Acute Kidney Injury according to KDIGO creatinine criteria.
Time frame: Seven days rolling window.
AKI by creatinine criteria is defined as any of the following: 1) Increase in SCr by ≥26.5 umol/l within 48 hours; or 2) Increase in SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days. Further, the severity of AKI is staged in 3 levels: 1) SCr 1.5-1.9 times baseline OR ≥26.5 umol/l increase; 2) SCr 2.0-2.9 times baseline; 3) SCr 3.0 times baseline OR increase in serum creatinine to ≥353.6 umol/l OR initiation of renal replacement therapy
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Dec 2024.
- Individual participant dataSharing planned: No. We are not allowed to share individual patient data according to decision in Swedish Ethical Review Authority. If a third party upon reasonable request present a valid authorization from the responsible government agency we might be allowed to share the data if we submit an amendment to the Swedish Ethical Review Authority.
Related trials for Acute Kidney Injury
Not yet recruiting
Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial
Acute-on-Chronic Liver Failure (ACLF)
Not yet recruiting
Early Biomarker Kidney Injury Assessment After Acumen Directed Fluid Management in Cardiac Surgery
Renal Injury, Acute Kidney Injury
Recruiting
Acute Kidney Injury and Ultra-endurance Running
AKI (Acute Kidney Injury) Due to Trauma
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Not yet recruitingObservational study
Diastolic Shock Index for Predicting Hemodynamic Instability During Continuous Renal Replacement Therapy
Acute Kidney Injury, Hypotension (MeSH: D007022)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Kidney Injury and Critical Illness, run by Uppsala University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 9 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mikael Eriksson, MD, PhD (+46186110000, mikael.e.eriksson@uu.se), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Acute Kidney Injury according to KDIGO creatinine criteria. (time frame: Seven days rolling window.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Dec 2024.